RU2015131137A - Производное амида коричной кислоты - Google Patents

Производное амида коричной кислоты Download PDF

Info

Publication number
RU2015131137A
RU2015131137A RU2015131137A RU2015131137A RU2015131137A RU 2015131137 A RU2015131137 A RU 2015131137A RU 2015131137 A RU2015131137 A RU 2015131137A RU 2015131137 A RU2015131137 A RU 2015131137A RU 2015131137 A RU2015131137 A RU 2015131137A
Authority
RU
Russia
Prior art keywords
substituted
carbon atoms
compound
propenamide
fluorophenyl
Prior art date
Application number
RU2015131137A
Other languages
English (en)
Inventor
Томохиро ООКУБО
Ко НАКАМУРА
Йоситака НАКАДЗАВА
Хиройоси НАНБА
Хироюки ЙОСИДА
Original Assignee
Ниппон Дзоки Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ниппон Дзоки Фармасьютикал Ко., Лтд. filed Critical Ниппон Дзоки Фармасьютикал Ко., Лтд.
Publication of RU2015131137A publication Critical patent/RU2015131137A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (56)

1. Соединение или его фармацевтически приемлемая соль или гидрат, где соединение представлено следующей общей формулой (I):
Figure 00000001
,
где n означает целое число от 0 до 4;
X1 и X2, являющиеся одинаковыми или различными, означают водород, фтор, трифторметил или карбокси, и один из X1 и X2 означает заместитель, иной чем водород;
R1 означает:
имидазолил, замещенный алкилом с 1-6 атомами углерода или фенилом;
пирролил, который может быть замещен алкилом с 1-4 атомами углерода;
фенил, замещенный амино, изоксазолилом или морфолино;
фенил, замещенный тиоморфолино, который может быть замещен оксо;
пиперазино, замещенный алкилом с 1-4 атомами углерода или циклогексилом;
тиоморфолино, который может быть замещен одним или двумя оксо; или
любой из заместителей, выбираемых из гуанидино, индазолила и циклогексиламино; и
R2 означает водород, циано или алкил с 1-4 атомами углерода, при условии, что в случае n=0, R1 означает заместитель, иной чем фенил, замещенный морфолино.
2. Соединение или его фармацевтически приемлемая соль или гидрат по п. 1, где R2 означает водород и где один из X1 и X2 означает водород, а другой означает фтор.
3. Соединение или его фармацевтически приемлемая соль или гидрат по п. 2, где R1 означает имидазолил, замещенный алкилом с 1-6 атомами углерода или фенилом.
4. Соединение или его фармацевтически приемлемая соль или гидрат по п. 2, где R1 означает пирролил, который может быть замещен алкилом с 1-4 атомами углерода.
5. Соединение или его фармацевтически приемлемая соль или гидрат по п. 2, где R1 означает фенил, замещенный амино, изоксазолилом или морфолино.
6. Соединение или его фармацевтически приемлемая соль или гидрат по п. 2, где R1 означает фенил, замещенный тиоморфолино, который может быть замещен оксо.
7. Соединение или его фармацевтически приемлемая соль или гидрат по п. 2, где R1 означает пиперазино, замещенный алкилом с 1-4 атомами углерода или циклогексилом.
8. Соединение или его фармацевтически приемлемая соль или гидрат по п. 2, где R1 означает тиоморфолино, который может быть замещен одним или двумя оксо.
9. Соединение или его фармацевтически приемлемая соль или гидрат по п. 2, где R1 означает любой из заместителей, выбираемых из гуанидино, индазолила и циклогексиламино.
10. Соединение или его фармацевтически приемлемая соль или гидрат по п. 1, которые выбирают из группы, состоящей из (E)-N-[2-(4-циклогексилпиперазин-1-ил)этил]-3-(2-фторфенил)-2-пропенамида, (E)-N-[3-(4-циклогексилпиперазин-1-ил)пропил]-3-(2-фторфенил)-2-пропенамида, (E)-3-(2-фторфенил)-N-[3-(4-метилпиперазин-1-ил)пропил]-2-пропенамида, (E)-3-(2-фторфенил)-N-[3-(изоксазол-5-ил)фенил]-2-пропенамида, (E)-3-(4-фторфенил)-N-(3-тиоморфолинопропил)-2-пропенамида, (E)-3-(2-фторфенил)-N-(3-тиоморфолинопропил)-2-пропенамида, (E)-N-[3-(1,1-диоксо-1,4-тиазинан-4-ил)пропил]-3-(2-фторфенил)-2-пропенамида, (E)-N-[3-(1,1-диоксо-1,4-тиазинан-4-ил)пропил]-3-(4-фторфенил)-2-пропенамида, (E)-3-(4-фторфенил)-N-[3-(1-оксо-1,4-тиазинан-4-ил)пропил]-2-пропенамида и (E)-3-(2-фторфенил)-N-[3-(1-оксо-1,4-тиазинан-4-ил)пропил]-2-пропенамида.
11. Соединение или его фармацевтически приемлемая соль или гидрат по п. 1, которые выбирают из группы, состоящей из (E)-3-(4-фторфенил)-N-(3-тиоморфолинопропил)-2-пропенамида, (E)-3-(2-фторфенил)-N-(3-тиоморфолинопропил)-2-пропенамида, (E)-3-(4-фторфенил)-N-[3-(1-оксо-1,4-тиазинан-4-ил)пропил]-2-пропенамида и (E)-3-(2-фторфенил)-N-[3-(1-оксо-1,4-тиазинан-4-ил)пропил]-2-пропенамида.
12. Фармацевтическое средство, включающее в качестве активного ингредиента, по меньшей мере одно соединение или его фармацевтически приемлимую соль или гидрат, где соединение представлено следующей общей формулой (I):
Figure 00000002
,
где n означает целое число от 0 до 4;
X1 и X2, являющиеся одинаковыми или различными, означают водород, фтор, трифторметил или карбокси, и один из X1 и X2 означает заместитель, иной чем водород;
R1 означает:
имидазолил, который может быть замещен алкилом с 1-6 атомами углерода или фенилом;
пирролил, который может быть замещен алкилом с 1-4 атомами углерода;
фенил, замещенный амино, алкокси с 1-4 атомами углерода, пиразолилом, изоксазолилом или морфолино;
фенил, замещенный тиоморфолино, который может быть замещен оксо;
пиперазино, который может быть замещен алкилом с 1-4 атомами углерода или циклогексилом;
тиоморфолино, который может быть замещен одним или двумя оксо; или
любой из заместителей, выбираемых из амино, карбокси, гуанидино, индолила, бензоимидазолила, индазолила, пиразолила, триазолила, пиридила, пирролидинила, пиперидино, гексаметиленимино, морфолино и циклогексиламино; и
R2 означает водород, циано или алкил с 1-4 атомами углерода.
13. Фармацевтическое средство по п. 12, которое представляет собой аналгетик.
14. Фармацевтическое средство по п. 13, где аналгетик представляет собой терапевтическое средство для лечения хронических болей.
15. Фармацевтическое средство по п. 14, где терапевтическое средство для лечения хронических болей представляет собой терапевтическое средство для лечения люмбаго, артралгии или невропатических болей.
16. Фармацевтическое средство по п. 13, где аналгетик представляет собой терапевтическое средство для лечения невропатических болей.
17. Фармацевтическое средство по любому из пп. 12-16, которое представляет собой пероральный препарат.
18. Фармацевтическое средство по любому из пп. 12-16, которое представляет собой инъекционный препарат.
19. Применение соединения или его фармацевтически приемлемой соли или гидрата в качестве фармацевтического средства, где соединение представлено следующей общей формулой (I):
Figure 00000003
,
где n означает целое число от 0 до 4;
X1 и X2, являющиеся одинаковыми или различными, означают водород, фтор, трифторметил или карбокси, и один из X1 и X2 означает заместитель, иной чем водород;
R1 означает:
имидазолил, который может быть замещен алкилом с 1-6 атомами углерода или фенилом;
пирролил, который может быть замещен алкилом с 1-4 атомами углерода;
фенил, замещенный амино, алкокси с 1-4 атомами углерода, пиразолилом, изоксазолилом или морфолино;
фенил, замещенный тиоморфолино, который может быть замещен оксо;
пиперазино, который может быть замещен алкилом с 1-4 атомами углерода или циклогексилом;
тиоморфолино, который может быть замещен одним или двумя оксо; или
любой из заместителей, выбираемых из амино, карбокси, гуанидино, индолила, бензоимидазолила, индазолила, пиразолила, триазолила, пиридила, пирролидинила, пиперидино, гексаметиленимино, морфолино и циклогексиламино; и
R2 означает водород, циано или алкил с 1-4 атомами углерода.
20. Применение по п. 19, где фармацевтическое средство представляет собой аналгетик.
RU2015131137A 2012-12-28 2013-12-27 Производное амида коричной кислоты RU2015131137A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-286935 2012-12-28
JP2012286935 2012-12-28
PCT/JP2013/085041 WO2014104272A1 (ja) 2012-12-28 2013-12-27 ケイ皮酸アミド誘導体

Publications (1)

Publication Number Publication Date
RU2015131137A true RU2015131137A (ru) 2017-02-02

Family

ID=51021343

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015131137A RU2015131137A (ru) 2012-12-28 2013-12-27 Производное амида коричной кислоты

Country Status (16)

Country Link
US (1) US9540338B2 (ru)
EP (1) EP2940003A4 (ru)
JP (1) JP6415985B2 (ru)
KR (1) KR20150100923A (ru)
CN (2) CN107573275A (ru)
AU (1) AU2013366974B2 (ru)
BR (1) BR112015015349A2 (ru)
CA (1) CA2896329A1 (ru)
HK (1) HK1214587A1 (ru)
IL (1) IL239570B (ru)
MX (1) MX2015007862A (ru)
RU (1) RU2015131137A (ru)
SG (1) SG11201505120UA (ru)
TW (1) TWI646072B (ru)
WO (1) WO2014104272A1 (ru)
ZA (1) ZA201504658B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105037318B (zh) * 2015-07-09 2018-10-12 北京颖泰嘉和生物科技股份有限公司 2-氰基-3-(2,2-二氟-1,3-苯并二氧-4-基)丙烯酸类化合物及其制备方法
CA3147397A1 (en) 2019-07-22 2021-01-28 Lupin Limited Macrocyclic compounds as sting agonists and methods and uses thereof
JPWO2022210190A1 (ru) * 2021-03-30 2022-10-06

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726266B2 (ru) * 1973-07-17 1982-06-03
US4568687A (en) * 1983-02-28 1986-02-04 American Cyanamid Company N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions
EP0117462A3 (en) * 1983-02-28 1986-08-20 American Cyanamid Company N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
JPH08248567A (ja) * 1995-03-14 1996-09-27 Konica Corp ハロゲン化銀写真感光材料
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
EP1264820A4 (en) * 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co amide compounds
CA2468544A1 (en) 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
EP1764358A3 (en) * 2001-12-10 2007-03-28 Amgen, Inc Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain
EP1581516A4 (en) * 2002-11-22 2007-10-17 Bristol Myers Squibb Co BENZYLAMIDE 3-HETEROCYCLIC DERIVATIVES AS POTASIC CHANNEL OPENING AGENTS
AU2003294441A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
DE102004039373A1 (de) * 2004-08-12 2006-02-23 Grünenthal GmbH Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
AU2006225496A1 (en) * 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2006102645A1 (en) * 2005-03-24 2006-09-28 Janssen Pharmaceutica, N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
US20070032475A1 (en) * 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
AU2007208819B2 (en) * 2006-01-24 2012-06-07 Nippon Zoki Pharmaceutical Co., Ltd. Novel histidine derivative
JP2007210974A (ja) * 2006-02-13 2007-08-23 Sankyo Co Ltd 置換されたウレア化合物を含有する医薬
WO2008005954A2 (en) 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
CA2658925C (en) * 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2008144933A1 (en) * 2007-05-29 2008-12-04 Université de Montréal Cinnamoyl inhibitors of transglutaminase
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
CN101730467A (zh) * 2007-07-06 2010-06-09 努恩治疗学股份有限公司 神经病性疼痛的治疗
WO2009096701A2 (en) * 2008-01-28 2009-08-06 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP2012510512A (ja) * 2008-12-03 2012-05-10 マサチューセッツ インスティテュート オブ テクノロジー 記憶を推進するためのｈｄａｃ２の阻害
HUE047515T2 (hu) * 2009-09-09 2020-04-28 Novaremed Ltd N-Szubsztituált benzolpropánamidok fájdalom és gyulladás kezelésében történõ alkalmazásra
US9518044B2 (en) * 2011-06-20 2016-12-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto

Also Published As

Publication number Publication date
CA2896329A1 (en) 2014-07-03
IL239570A0 (en) 2015-08-31
IL239570B (en) 2018-05-31
AU2013366974A1 (en) 2015-07-09
KR20150100923A (ko) 2015-09-02
US9540338B2 (en) 2017-01-10
HK1214587A1 (zh) 2016-07-29
AU2013366974B2 (en) 2017-11-02
JP6415985B2 (ja) 2018-10-31
EP2940003A4 (en) 2017-03-08
ZA201504658B (en) 2021-09-29
CN107573275A (zh) 2018-01-12
MX2015007862A (es) 2016-02-05
CN104884426A (zh) 2015-09-02
SG11201505120UA (en) 2015-08-28
JPWO2014104272A1 (ja) 2017-01-19
WO2014104272A1 (ja) 2014-07-03
EP2940003A1 (en) 2015-11-04
US20150322024A1 (en) 2015-11-12
BR112015015349A2 (pt) 2017-07-11
TWI646072B (zh) 2019-01-01
TW201439044A (zh) 2014-10-16

Similar Documents

Publication Publication Date Title
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
RU2485131C2 (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
WO2013009810A1 (en) Methods of treatment
RU2017116197A (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера
RU2009118602A (ru) Производное индола
JP2017523972A5 (ru)
RU2008105304A (ru) Соединение бензоимидазола, способное к ингибированию простагландин-d-синтетазы
WO2013009830A1 (en) Methods of treatment
RU2008109908A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
NZ590268A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
JP2010514832A5 (ru)
JP2007532607A5 (ru)
RU2006124403A (ru) Новые производные тиазола
RU2015101210A (ru) Производные тиофена, используемые для лечения сахарного диабета
JP2016540742A5 (ru)
RU2015127822A (ru) Ингибиторы энхансера гомолога 2 белка zeste
RU2010142936A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРАЗИНА КАК ИНГИБИТОРЫ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ
JP2018502101A5 (ru)
RU2007103831A (ru) Производные пиразола
NZ603724A (en) Piperidine derivatives and their use for the treatment of metabolic disorders
RU2015117647A (ru) Новые производные пиразола
JP2016540811A5 (ru)
HRP20191940T1 (hr) Inhibitori c-terminalnog hsp90
RU2015131137A (ru) Производное амида коричной кислоты

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20181009